Cargando…
Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants
The Food and Drug Administration (FDA) has approved MAPK inhibitors as a treatment for melanoma patients carrying a mutation in codon V600 of the BRAF gene exclusively. However, BRAF mutations outside the V600 codon may occur in a small percentage of melanomas. Although these rare variants may cause...
Autores principales: | Scaini, Maria Chiara, Piccin, Luisa, Bassani, Davide, Scapinello, Antonio, Pellegrini, Stefania, Poggiana, Cristina, Catoni, Cristina, Tonello, Debora, Pigozzo, Jacopo, Dall’Olmo, Luigi, Rosato, Antonio, Moro, Stefano, Chiarion-Sileni, Vanna, Menin, Chiara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418914/ https://www.ncbi.nlm.nih.gov/pubmed/37569660 http://dx.doi.org/10.3390/ijms241512285 |
Ejemplares similares
-
Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
por: Catoni, Cristina, et al.
Publicado: (2022) -
Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy
por: Aleotti, Valentina, et al.
Publicado: (2021) -
The Interplay between Nevi and Melanoma Predisposition Unravels Nevi-Related and Nevi-Resistant Familial Melanoma
por: Pellegrini, Stefania, et al.
Publicado: (2021) -
Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015) -
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
por: Valpione, Sara, et al.
Publicado: (2018)